Viloxazine in the treatment of depressive neurosis: A placebo and standard (imipramine) controlled clinical study

W. M. Petrie, Joseph Patrick McEvoy, W. H. Wilson, T. A. Ban, W. Guy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In a 4-week double-blind trial, 33 patients with depressive neurosis were randomly assigned to either viloxazine, imipramine or placebo. Statistically significant improvement was observed in all treatment groups. Imipramine exhibited significant improvement earlier in depressive symptoms, while viloxazine showed significant improvement earlier in anxious symptoms. The same frequency of treatment emergent symptoms occurred in the treatment groups. Premature termination as a consequence of adverse reactions was required in only 1 viloxazine and 1 placebo patient.

Original languageEnglish (US)
Pages (from-to)193-196
Number of pages4
JournalUnknown Journal
Volume15
Issue number3
DOIs
StatePublished - Jan 1 1980
Externally publishedYes

Fingerprint

Viloxazine
neurosis
Imipramine
Depressive Disorder
Placebos
Group
Therapeutics
Depression
Clinical Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Viloxazine in the treatment of depressive neurosis : A placebo and standard (imipramine) controlled clinical study. / Petrie, W. M.; McEvoy, Joseph Patrick; Wilson, W. H.; Ban, T. A.; Guy, W.

In: Unknown Journal, Vol. 15, No. 3, 01.01.1980, p. 193-196.

Research output: Contribution to journalArticle

@article{b04bd7060fa34ea4af2928d7fdb60e86,
title = "Viloxazine in the treatment of depressive neurosis: A placebo and standard (imipramine) controlled clinical study",
abstract = "In a 4-week double-blind trial, 33 patients with depressive neurosis were randomly assigned to either viloxazine, imipramine or placebo. Statistically significant improvement was observed in all treatment groups. Imipramine exhibited significant improvement earlier in depressive symptoms, while viloxazine showed significant improvement earlier in anxious symptoms. The same frequency of treatment emergent symptoms occurred in the treatment groups. Premature termination as a consequence of adverse reactions was required in only 1 viloxazine and 1 placebo patient.",
author = "Petrie, {W. M.} and McEvoy, {Joseph Patrick} and Wilson, {W. H.} and Ban, {T. A.} and W. Guy",
year = "1980",
month = "1",
day = "1",
doi = "10.1159/000468437",
language = "English (US)",
volume = "15",
pages = "193--196",
journal = "Handbook of Behavioral Neuroscience",
issn = "0003-1348",
publisher = "JAI Press",
number = "3",

}

TY - JOUR

T1 - Viloxazine in the treatment of depressive neurosis

T2 - A placebo and standard (imipramine) controlled clinical study

AU - Petrie, W. M.

AU - McEvoy, Joseph Patrick

AU - Wilson, W. H.

AU - Ban, T. A.

AU - Guy, W.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - In a 4-week double-blind trial, 33 patients with depressive neurosis were randomly assigned to either viloxazine, imipramine or placebo. Statistically significant improvement was observed in all treatment groups. Imipramine exhibited significant improvement earlier in depressive symptoms, while viloxazine showed significant improvement earlier in anxious symptoms. The same frequency of treatment emergent symptoms occurred in the treatment groups. Premature termination as a consequence of adverse reactions was required in only 1 viloxazine and 1 placebo patient.

AB - In a 4-week double-blind trial, 33 patients with depressive neurosis were randomly assigned to either viloxazine, imipramine or placebo. Statistically significant improvement was observed in all treatment groups. Imipramine exhibited significant improvement earlier in depressive symptoms, while viloxazine showed significant improvement earlier in anxious symptoms. The same frequency of treatment emergent symptoms occurred in the treatment groups. Premature termination as a consequence of adverse reactions was required in only 1 viloxazine and 1 placebo patient.

UR - http://www.scopus.com/inward/record.url?scp=0019295228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019295228&partnerID=8YFLogxK

U2 - 10.1159/000468437

DO - 10.1159/000468437

M3 - Article

C2 - 7016802

AN - SCOPUS:0019295228

VL - 15

SP - 193

EP - 196

JO - Handbook of Behavioral Neuroscience

JF - Handbook of Behavioral Neuroscience

SN - 0003-1348

IS - 3

ER -